Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 1999
Business Overview: Myriad Genetics operates in two primary segments: Research (gene discovery, sequencing, and therapeutic product development) and Molecular Diagnostics (testing for disease predisposition, notably BRACAnalysis and CardiaRisk). The company relies heavily on collaborative research agreements with major pharmaceutical entities (e.g., Novartis, Bayer, Schering, Monsanto) for funding and milestone payments.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1999 | Six Months Ended Dec 31, 1999 |
|---|---|---|
| Total Revenues | $8,279,743 | $15,141,674 |
| Net Loss | ($1,877,150) | ($4,068,242) |
| Operating Loss | ($2,268,825) | ($5,018,613) |
| Cash and Cash Equivalents | $27,679,996 (Balance Sheet) | $27,679,996 (Balance Sheet) |
| Total Marketable Securities | $32,362,511 (Current + Long-term) | $32,362,511 (Current + Long-term) |
| Net Cash Provided by Operating Activities | N/A | $11,540,201 |
| Accumulated Deficit | ($48,008,122) | ($48,008,122) |
Liquidity: As of December 31, 1999, the company held approximately $60 million in cash, cash equivalents, and marketable investment securities. The company reported no long-term debt on the balance sheet, though it maintains a Master Lease Agreement with Comdisco subject to financial covenants.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 44% for the quarter and 34% for the six-month period compared to the prior year.
- Research Revenue: Increased from $4.54M to $6.26M (quarter) and $9.18M to $11.50M (six months), driven primarily by the Novartis Agricultural Discovery Institute (NADII) collaboration initiated in July 1999.
- Molecular Diagnostic Revenue: Increased 67% for the quarter ($2.02M vs $1.21M) and 71% for the six months ($3.64M vs $2.12M), attributed to expanded sales and marketing efforts.
- Expense Increases:
- R&D Expenses: Rose to $6.21M (quarter) and $11.99M (six months) due to increased activity from the NADII collaboration and drug discovery efforts.
- Selling, General & Administrative (SG&A): Increased to $3.35M (quarter) and $6.38M (six months) due to sales force expansion, recruiting costs, and patent filing expenses.
- Deferred Revenue: Increased significantly from $662,760 to $12,629,422, largely due to upfront payments received from collaborators (specifically NADII) that have not yet been recognized as revenue.
- Asset Disposition: Recorded a loss of $344,989 for the quarter and $360,082 for the six months on the disposition of unproductive assets.
Guidance, Outlook, and Risks
- Outlook: Management expects to incur losses for at least the next several years due to the expansion of R&D programs, drug discovery efforts, and facility expansion. The company anticipates that existing capital resources will be adequate for at least the next two years.
- New Collaborations:
- Hoffmann-LaRoche: Entered a 12-month collaboration in December 1999 for cardiovascular disease research (potential value up to $13 million).
- Schering AG: Expanded collaboration to include cardiovascular disease research and sold 303,030 shares of common stock for $5 million in October 1999.
- Year 2000 Compliance: The company completed Year 2000 readiness testing by December 31, 1999, and reported no significant problems. However, risks remain regarding supplier and customer compliance.
- Accounting Changes: The company noted the issuance of SEC Staff Accounting Bulletin No. 101 (SAB 101) regarding revenue recognition, which will be incorporated in the first quarter of fiscal 2001. The impact is currently undetermined.
- Risks: Key risks include the uncertainty of reimbursement for molecular diagnostic tests, intense competition in gene discovery, the high cost of developing therapeutic lead compounds, and the potential failure to secure future collaborative agreements.
Investor Verification Checklist
- Deferred Revenue Recognition: Verify the timeline and conditions for recognizing the $12.6 million in deferred revenue, particularly regarding the NADII upfront payment.
- Cash Burn Rate: Assess the sustainability of the current cash position ($60M) against the projected continued losses and capital requirements for drug development.
- Collaboration Milestones: Monitor the progress of major collaborations (Novartis, Bayer, Schering, Monsanto) to ensure milestone payments are met and not at risk of termination.
- Year 2000 Contingencies: Confirm that no material disruptions occurred post-December 31, 1999, related to third-party systems or supply chains.
- SAB 101 Impact: Review the upcoming fiscal 2001 filings to determine the impact of new revenue recognition standards on reported earnings.